Evidence map›Paper›PMID 24567297›Full record

ArticleThorax2014

Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.

Elizabeth K Sage, Krishna K Kolluri, Katrina McNulty, Sofia Da Silva Lourenco, Tammy L Kalber, Katherine L Ordidge, Derek Davies, Y C Gary Lee, Adam Giangreco, Sam M Janes

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thorax, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 65 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Intravenously Infused Stem Cells for Cancer Treatment.Stem cell reviews and reports · 2021
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. CD90Oncotarget · 2019
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Elizabeth K SageDivision of Medicine, Lungs for Living Research Centre, University College London, London, UK.
Krishna K KolluriDivision of Medicine, Lungs for Living Research Centre, University College London, London, UK.
Katrina McNultyDivision of Medicine, Lungs for Living Research Centre, University College London, London, UK.
Sofia Da Silva LourencoDivision of Medicine, Lungs for Living Research Centre, University College London, London, UK.
Tammy L KalberDivision of Medicine, Lungs for Living Research Centre, University College London, London, UK Division of Medicine and Institute of Child Health, UCL Centre of Advanced Biomedical Imaging, University College London, London, UK.
Katherine L OrdidgeDivision of Medicine, Lungs for Living Research Centre, University College London, London, UK Division of Medicine and Institute of Child Health, UCL Centre of Advanced Biomedical Imaging, University College London, London, UK.
Derek DaviesFlow Cytometry Laboratory, Cancer Research UK, London Research Institute, London, UK.
Y C Gary LeeSchool of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Australia.
Adam GiangrecoDivision of Medicine, Lungs for Living Research Centre, University College London, London, UK.
Sam M JanesDivision of Medicine, Lungs for Living Research Centre, University College London, London, UK.
University College London · GBCancer Research UK · GBUniversity of Western Australia · AU

Funding

European Research Council 260290Medical Research Council G1000355Wellcome Trust 091730Wellcome Trust WT091730AIA
6 · The paper itself

Abstract

Malignant pleural mesothelioma is a rare but devastating cancer of the pleural lining with no effective treatment. The tumour is often diffusely spread throughout the chest cavity, making surgical resection difficult, while systemic chemotherapy offers limited benefit. Bone marrow-derived mesenchymal stem cells (MSCs) home to and incorporate into tumour stroma, making them good candidates to deliver anticancer therapies. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic molecule that selectively induces apoptosis in cancer cells, leaving healthy cells unaffected. We hypothesised that human MSCs expressing TRAIL (MSCTRAIL) would home to an in vivo model of malignant pleural mesothelioma and reduce tumour growth. Human MSCs transduced with a lentiviral vector encoding TRAIL were shown in vitro to kill multiple malignant mesothelioma cell lines as predicted by sensitivity to recombinant TRAIL (rTRAIL). In vivo MSC homing was delineated using dual fluorescence and bioluminescent imaging, and we observed that higher levels of MSC engraftment occur after intravenous delivery compared with intrapleural delivery of MSCs. Finally, we show that intravenous delivery of MSCTRAIL results in a reduction in malignant pleural mesothelioma tumour growth in vivo via an increase in tumour cell apoptosis.

Indexed as

Administration, TopicalAnimalsApoptosisCell MovementCell ProliferationFemaleFlow CytometryHumansImmunohistochemistryInfusions, IntravenousLung NeoplasmsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMesotheliomaMesothelioma, MalignantMiceTNF-Related Apoptosis-Inducing LigandAsbestos Induced Lung DiseaseLung CancerMesotheliomaOccupational Lung Disease

Identifiers

PMID24567297
PMCPMC4078753
OpenAlexW2114181696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.